Email Alert | RSS

北京大学学报（医学版） ›› 2019, Vol. 51 ›› Issue (6): 1008-1013. doi: 10.19723/j.issn.1671-167X.2019.06.005

• 论著 • 上一篇    下一篇

类风湿因子或抗环瓜氨酸化多肽抗体阳性银屑病关节炎患者的临床特点

代丽怡1,巩丹丹2,赵金霞1,△()   

  1. 1. 北京大学第三医院风湿免疫科,北京　100191
    2. 邯郸市第一医院风湿免疫科,河北邯郸　056000
  • 收稿日期:2019-08-26 出版日期:2019-12-18 发布日期:2019-12-19
  • 通讯作者: 赵金霞 E-mail:zhao-jinxia@163.com

Clinical characteristics of psoriatic arthritis with positive rheumatoid factor or anti-cyclic citrullinated peptide antibody

Li-yi DAI1,Dan-dan GONG2,Jin-xia ZHAO1,△()   

  1. 1. Department of Rheumatology, Peking University Third Hospital, Beijing 100191, China
    2. Department of Rheumatology, Handan First Hospital, Handan 056000, Hebei, China
  • Received:2019-08-26 Online:2019-12-18 Published:2019-12-19
  • Contact: Jin-xia ZHAO E-mail:zhao-jinxia@163.com

RICH HTML

 22   

PDF (PC)

288

摘要：

目的 分析类风湿因子(rheumatoid factor,RF)或抗环瓜氨酸化多肽(cyclic-citrullinated peptide,CCP)抗体阳性银屑病关节炎(psoriatic arthritis,PsA)患者的临床和实验室检查特点。方法 共纳入2007年1月至2019年6月于北京大学第三医院风湿免疫科住院的PsA患者77例,所有患者均符合2006年美国风湿病学会修订的《银屑病关节炎的分类诊断标准》或《Moll和Wright标准》,并进行了RF及抗CCP抗体检测,根据血清中是否检测到抗CCP抗体或RF将所有患者分为抗CCP抗体或RF阳性组15例、抗CCP抗体或RF阴性组62例;根据血清中是否检测到抗CCP抗体将所有患者分为抗CCP抗体阳性组7例、抗CCP抗体阴性组70例,收集患者的临床及实验室资料,比较RF或抗CCP抗体阳性和阴性PsA患者的临床及实验室指标的差异,并单独比较了抗CCP抗体阳性和阴性PsA患者的临床及实验室指标的差异。结果 在77例患者中,RF或抗CCP抗体阳性者15例,其中仅RF阳性者8例,仅抗CCP抗体阳性者2例,两者均为阳性者5例。RF或抗CCP抗体阳性组PsA患者年龄较阴性组大[(58.2±14.8)岁 vs.(46.69±12.27)岁,P=0.002],更易出现掌指关节、肘关节、肩关节受累。抗CCP抗体阳性组PsA患者较阴性组年龄大[(62.43±14.34)岁vs.(47.59±12.75)岁,P=0.005],RF阳性率高,血纤维蛋白原水平高。抗CCP抗体阳性组PsA患者均为多关节炎,阴性组患者中有68.6%的患者为多关节炎,但两组间差异无统计学意义。RF或抗CCP抗体阳性和阴性以及抗CCP抗体阳性和阴性组PsA患者在腊肠指/趾表现、关节骨质破坏、指/趾甲改变、附着点炎方面差异无统计学意义。结论 部分PsA患者血清中可检测到RF或抗CCP抗体;RF或抗CCP抗体阳性PsA患者更易出现掌指关节、肘关节、肩关节受累,年龄更大;抗CCP抗体阳性PsA患者年龄更大,RF阳性率、纤维蛋白原水平高。

关键词: 银屑病关节炎, 类风湿因子, 抗环瓜氨酸化多肽抗体

Abstract:

Objective: To analyze the clinical and laboratory features of psoriatic arthritis (PsA) patients with positive rheumatoid factor(RF)or anti-cyclic citrullinated peptide(CCP)antibody.Methods: In the study, 77 PsA patients who were hospitalized in the Department of Rheumatology and Immunology of Peking University Third Hospital from January 2007 to June 2019 were enrolled. All the patients met Classification Criteria for Psoriatic Arthritis or Moll or Wright Criteria. Rheumatoid factor (RF) and anti-cyclic-citrullinated peptide (CCP) antibody were tested in these patients. According to whether anti-CCP antibody or RF was detected in serum, all the patients were divided into anti-CCP antibody or RF positive group (15 cases), anti-CCP antibody or RF negative group (62 cases). According to the detection of anti-CCP antibody in serum, all the patients were divided into anti-CCP antibody positive group (7 cases) and anti-CCP antibody negative group (70 cases). Clinical and laboratory data were collected. The differences of clinical and laboratory indicators between the RF or anti-CCP antibody positive and negative PsA patients were compared. Clinical and laboratory indicators between the anti-CCP antibody positive and negative patients were also compared.Results: Among the 77 patients, 15 were RF or anti-CCP antibody positive, of whom 8 were only RF positive and 2 were only anti-CCP antibody positive, and both of RF and anti-CCP antibody were positive in 5 cases. The RF or anti-CCP antibody positive PsA patients were older than those in the negative group [(58.2±14.8) years vs.(46.69±12.27)years, P=0.002]. And metacarpophalangeal joints, elbow joints and shoulder joints were more likely to be involved in RF or anti-CCP antibody positive PsA patients. PsA patients in the anti-CCP antibody positive group were older than those in the negative group [(62.43±14.34) years vs.(47.59±12.75)years old, P=0.005]. The positive rate of RF and serum level of fibrinogen in the anti-CCP antibody positive group were higher than those in the negative group. The PsA patients in the anti-CCP antibody positive group were all polyarthritis, while 68.6% patients in the negative group were polyarthritis, but there was no statistical difference between the two groups. There was no statistical difference in sausage fingers/toes, changes in nails and enthesitis, and bone erosion on radiographs between the RF or anti-CCP antibody positive and negative PsA patients. There was also no statistical difference in sausage fingers/toes,bone erosion on radiographs,and changes in nails and enthesitis between the anti-CCP antibody positive and negative patients.Conclusion: RF and anti-CCP antibodies can be detected in the serum of some PsA patients. RF or anti-CCP antibody positive PsA patients were older than those in negative PsA patients. Metacarpophalangeal joints, elbow joints and shoulder joints were more likely to be involved in RF or anti-CCP antibody positive PsA patients. Anti-CCP antibody positive PsA patients were older and had higher levels of RF positive rate and fibrinogen level.

Key words: Psoriatic arthritis, Rheumatoid factor, Anti-cyclic citrullinated peptide antibody

中图分类号: 

  • R593.2

表1

RF或抗CCP抗体阳性及阴性PsA患者基本情况的比较"

Items Positive group(n=15) Negative group(n=62) P
Male,n(%) 9(60.0) 35(56.45) 0.803*
Age /years, x?±s 58.2±14.8 46.69±12.27 0.002
The course of psoriasis/years, x?±s 15.04±12.57 13.79±12.41 0.727
The course of arthritis/years, M(Min, Max) 2(0.08,18.00) 1(0.02,20.00) 0.517

表2

RF或抗CCP抗体阳性及阴性PsA患者临床特点的比较"

Items Positive group(n=15) Negative group(n=62) P
Shoulder joint involvement, n(%) 9(60.0) 16(25.8) 0.026#
Elbow joint involvement, n(%) 7(46.7) 11(17.7) 0.042#
Wrist joint involvement, n(%) 10(66.7) 26(41.9) 0.085*
MCP joint involvement, n(%) 11(73.3) 24(38.7) 0.016*
PIP joint involvement, n(%) 12(80.0) 33(53.2) 0.059*
DIP joint involvement, n(%) 6(40.0) 22(35.5) 0.744*
Hip joint involvement, n(%) 2(13.3) 7(11.3) 1.000#
Knee joint involvement, n(%) 11(73.3) 36(58.1) 0.277*
Ankle joint involvement, n(%) 6(40.0) 20(32.3) 0.569*
MTP joint involvement, n(%) 8(53.3) 23(37.1) 0.250*
PIP joint involvement of foot, n(%) 1(6.7) 15(24.2) 0.252#
DIP joint involvement of foot, n(%) 0(0.0) 9(14.5) 0.262#
Spinal involvement, n(%) 2(13.3) 7(11.3) 1.000#
Sacroiliac joint involvement, n(%) 2(13.3) 12(19.4) 0.865#
More than 3 articular regions involvement (14 articular regions), n(%) 13(86.7) 42(67.7) 0.255#
Wrist, MCP or PIP (hand) joint involvement, n(%) 14(93.3) 47(75.8) 0.252#
Symmetrical arthritis, n(%) 12(80.0) 34(54.8) 0.075*
Oligoarthritis (4 or less joints involved) , n(%) 2(13.3) 17(27.4) 0.423#
Sausage fingers/toes, n(%) 5(33.3) 18(30.5)(n=59) 1.000#
Changes in nails, n(%) 6(50.0)(n=12) 12(27.9)(n=43) 0.274#
Enthesitis, n(%) 2(16.7)(n=12) 15(34.9)(n=43) 0.393#
Psoriasis rash, n(%) 12(100.0)(n=12) 39(90.7)(n=43) 0.566▲

表3

RF或抗CCP抗体阳性及阴性PsA患者实验室及影像学检查的比较"

Items Seropositive group(n=15) Seronegative group(n=62) P
ESR/(mm/h), x?±s 55.15±30.89(n=13) 39.09±30.51(n=55) 0.067
CRP/(mg/L), x?±s 46.95(2.10, 173.00)(n=14) 24.70(1.00, 551.00)(n=59) 0.245
IgG/(g/L), x?±s 15.97±4.44(n=12) 13.47±3.02(n=45) 0.054
IgA/(g/L), x?±s 3.25±1.52(n=12) 3.23±1.28(n=46) 0.963
IgM/(g/L), x?±s 1.35±1.05(n=11) 1.15±0.53(n=45) 0.789
Fibrinogen/(g/L), x?±s 4.97±1.51(n=12) 4.38±1.38(n=44) 0.231
D-dimer/(mg/L), M(Min, Max) 0.78(0.11, 2.86)(n=12) 0.31(0, 2.76)(n=42) 0.121
Bone erosion on radiograph,n(%) 4(33.3)(n=12) 19(35.8)(n=53) 1.000#

表4

抗CCP抗体阳性及阴性PsA患者一般情况的比较"

Items Anti-CCP antibody positive group
(n=7)		 Anti-CCP antibody negative group
(n=70)		 P
Male,n(%) 5(71.4) 39(55.7) 0.689#
Age /years, x?±s 62.43±14.34 47.59±12.75 0.005
The course of psoriasis/years, x?±s 13.14±6.20 14.13±12.85 0.873
The course of arthritis/years, M(Min, Max) 2(0.83, 18) 1(0.02, 20) 0.871
Duration between skin onset and arthritis onset/years, M(Min, Max) 7.9(-1, 20)(n=7) 9.3(-2, 45)(n=64) 0.825

表5

抗CCP抗体阳性及阴性PsA患者临床特点的比较"

Items Anti-CCP antibody positive
group(n=7)		 Anti-CCP antibody negative
group(n=70)		 P
Shoulder joint involvement, n(%) 5(71.4) 20(28.6) 0.059#
Elbow joint involvement, n(%) 4(57.1) 14(20.0) 0.081#
Wrist joint involvement, n(%) 6(85.7) 30(42.9) 0.077#
MCP joint involvement, n(%) 6(85.7) 29(41.4) 0.065#
PIP joint involvement, n(%) 7(100.0) 38(54.3) 0.053#
DIP joint involvement, n(%) 3(42.9) 25(35.7) 1.000#
Hip joint involvement, n(%) 1(14.3) 8(11.4) 1.000▲
Knee joint involvement, n(%) 5(71.4) 42(60.0) 0.853#
Ankle joint involvement, n(%) 2(28.6) 24(34.3) 1.000#
MTP joint involvement, n(%) 3(42.9) 28(40.0) 1.000#
PIP joint involvement of foot, n(%) 1(14.3) 15(21.4) 1.000#
DIP joint involvement of foot, n(%) 0(0) 9(12.9) 0.590▲
Spinal involvement, n(%) 1(14.3) 8(11.4) 1.000▲
Sacroiliac joint involvement, n(%) 0(0) 14(20.0) 0.427#
More than 3 articular regions involvement(14 articular regions), n(%) 7(100.0) 48(68.6) 0.188#
Wrist, MCP or PIP(hand) joint involvement, n(%) 7(100.0) 54(77.1) 0.351#
Symmetrical arthritis , n(%) 6(85.7) 40(57.1) 0.287#
Oligoarthritis (4 or less joints involved), n(%) 0(0) 19(27.1) 0.259#
Sausage fingers/toes, n(%) 2(28.6)(n=7) 21(31.3)(n=67) 1.000#
Changes in nails, n(%) 2(50.0) (n=4) 16(31.4)(n=51) 0.833#
Enthesitis, n(%) 0(0) (n=4) 17(33.3)(n=51) 0.408#
Psoriasis rash, n(%) 4(100.0)(n=4) 47(92.2)(n=51) 1.000▲

表6

抗CCP抗体阳性及阴性PsA患者实验室及影像学检查的比较"

Items Anti-CCP antibody positive group(n=7) Anti-CCP antibody negative group(n=70) P
RF positive, n(%) 5(71.4) 8(11.4) <0.001#
ESR/(mm/h), x?±s 58.33±40.02(n=6) 40.60±29.95(n=62) 0.283
CRP/(mg/L), M(Min, Max) 69.2(2.1, 173.0)(n=7) 23.9(1.0, 551.0)(n=66) 0.459
IgG/(g/L), x?±s 13.90±4.10(n=5) 14.01±3.46(n=52) 0.902
IgA/(g/L), x?±s 3.57±2.02(n=5) 3.20±1.26(n=53) 0.687
IgM/(g/L), x?±s 1.50±1.58(n=5) 1.16±0.52(n=51) 0.635
Fibrinogen/(g/L), x?±s 5.87±1.30(n=4) 4.40±1.38(n=52) 0.048
D-dimer(mg/L), M(Min, Max) 0.92(0.59, 2.86)(n=4) 0.31(0, 2.76)(n=50) 0.071
Bone erosion on radiograph, n(%) 3(42.9)(n=7) 20(34.5)(n=58) 0.985#
[1] Korendowych E, Owen P, Ravindran J , et al. The clinical and genetic associations of anti-cyclic citrullinated peptide antibodies in psoriatic arthritis[J]. Rheumatology(Oxford), 2005,44(8):1056-1060.
[2] vander Cruyssen B, Hoffman IEA, Zmierczak H , et al. Anti-citrullinated peptide antibodies may occur in patients with psoriatic arthritis[J]. Ann Rheum Dis, 2005,64(8):1145-1149.
[3] Behrens F, Koehm M, Thaci D . Anti-citrullinated protein antibo-dies are linked to erosive disease in an observational study of patients with psoriatic arthritis[J]. Rheumatology, 2016,55(10):1791-1795.
[4] Hagiwara S, Tsuboi H, Terasaki T , et al. Association of anti-cyclic citrullinated peptide antibody with clinical features in patients with psoriatic arthritis[J]. Mod Rheumatol, 2019,29:1-8.
[5] Inanc N, Dalkilic E, Kamali S , et al. Anti-CCP antibodies in rheumatoid arthritis and psoriatic arthritis[J]. Clin Rheumatol, 2007,26(1):17-23.
[6] Taylor W, Gladman D, Helliwell P . Classification criteria for psoriatic arthritis: Development of new criteria from a large international study[J]. Arthritis Rheum, 2006,54(8):2665-2673.
[7] Moll JM, Wright V . Psoriatic arthritis[J]. Semin Arthritis Rheum, 1973,3(1):55-78.
[8] Aletaha D, Neogi T, Silman AJ , et al. 2010 rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative[J]. Arthritis Rheum, 2010,62(9):2569-2581.
[9] Zhao J, Su Y, Li R , et al. Classification criteria of early rheumatoid arthritis and validation of its performance in a multi-centre cohort[J]. Clin Exp Rheumatol, 2014,32(5):667-673.
[10] Inui K, Okano T, Yoshimura H , et al. Clinical features of rheumatoid factor- or anti-cyclic citrullinated peptides-positive patients with psoriatic arthritis[J]. Ann Rheum Dis, 2017,76(Suppl 2):1324.
[11] Eker YÖ, Pamuk ON, Pamuk GE , et al. The frequency of anti-CCP antibodies in patients with rheumatoid arthritis and psoriatic arthritis and their relationship with clinical features and parameters of angiogenesis: A comparative study[J]. Eur J Rheumatol, 2014,1(2):67-71.
[12] Popescu C, Zofota S, Bojinca V , et al. Anti-cyclic citrullinated peptide antibodies in psoriatic arthritis: Cross-sectional study and literature review[J]. J Med Life, 2013,6(4):376-382.
[13] Ritchlin CT, Colbert RA, Gladman DD . Psoriatic arthritis[J]. New Engl J Med, 2017,376(10):957-970.
[14] OzdemirIsik O, Cosan F, Yazici A , et al. The clinical assessment of anti-cyclic citrullinated peptide antibodies in psoriatic arthritis[J]. Ann Rheum Dis, 2016,75(Suppl 2):1151
[15] Merola JF, Espinoza LR, Fleischmann R . Distinguishing rheumatoid arthritis from psoriatic arthritis[J]. RMD Open, 2018,4(2):1-13.
[1] 宋志博,耿研,邓雪蓉,张晓慧,张卓莉. 肌肉骨骼超声在指导银屑病关节炎临床分型中的价值[J]. 北京大学学报（医学版）, 2021, 53(6): 1061-1066.
[2] 耿研,宋志博,张晓慧,邓雪蓉,王昱,张卓莉. 银屑病关节炎抑郁和焦虑患病情况及相关因素[J]. 北京大学学报（医学版）, 2020, 52(6): 1048-1055.
[3] 张警丰,叶修玲,段萌,周小利,姚中强,赵金霞. 抗核抗体阳性类风湿关节炎的临床和实验室检查特点[J]. 北京大学学报（医学版）, 2020, 52(6): 1023-1028.
[4] 李玉慧,苏波,林福安,费雅楠,于笑霞,范文强,陈海英,张学武,贾园. 银屑病关节炎患者就医行为及治疗现状的多中心调查[J]. 北京大学学报（医学版）, 2019, 51(6): 1014-1018.
[5] 苏茵，朱华群. 重视临床前期类风湿关节炎[J]. 北京大学学报(医学版), 2016, 48(6): 929-932.
[6] 曲世晶， 叶华， 贾汝琳， 栗占国. 血清学阴性类风湿关节炎关节液中抗环瓜氨酸肽抗体、抗突变型瓜氨酸波形蛋白抗体的测定及临床意义[J]. 北京大学学报(医学版), 2016, 48(6): 933-936.
[7] 石连杰，李建红，胡凡磊，李敏，张杰，李江涛，栗占国. 趋化因子配体19在类风湿关节炎患者血清中的表达及临床意义[J]. 北京大学学报(医学版), 2016, 48(4): 667-671.
[8] 穆荣, 孙晓云, 栗占国. 类风湿因子和抗环瓜氨酸多肽抗体联合检测在类风湿关节炎诊断中的意义[J]. 北京大学学报（医学版）, 2005, 37(5): 498-500.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
[1] 田增民, 陈涛, Nanbert ZHONG, 李志超, 尹丰, 刘爽. 神经干细胞移植治疗遗传性小脑萎缩的临床研究（英文稿）[J]. 北京大学学报（医学版）, 2009, 41(4): 456 -458 .
[2] 郭岩, 谢铮. 用一代人时间弥合差距——健康社会决定因素理论及其国际经验[J]. 北京大学学报（医学版）, 2009, 41(2): 125 -128 .
[3] 卢恬, 朱晓辉, 柳世庆, 郑杰, 邱晓彦. 白细胞介素2促进宫颈癌细胞系HeLaS3免疫球蛋白G的表达[J]. 北京大学学报（医学版）, 2009, 41(2): 158 -161 .
[4] 袁惠燕, 张苑, 范田园. 离子交换型栓塞微球及其载平阳霉素的制备与性质研究[J]. 北京大学学报（医学版）, 2009, 41(2): 217 -220 .
[5] 徐莉, 孟焕新, 张立, 陈智滨, 冯向辉, 释栋. 侵袭性牙周炎患者血清中抗牙龈卟啉单胞菌的IgG抗体水平的研究[J]. 北京大学学报（医学版）, 2009, 41(1): 52 -55 .
[6] 董稳, 刘瑞昌, 刘克英, 关明, 杨旭东. 氯诺昔康和舒芬太尼用于颌面外科术后自控静脉镇痛的比较[J]. 北京大学学报（医学版）, 2009, 41(1): 109 -111 .
[7] 祁琨, 邓芙蓉, 郭新彪. 纳米二氧化钛颗粒对人肺成纤维细胞缝隙连接通讯的影响[J]. 北京大学学报（医学版）, 2009, 41(3): 297 -301 .
[8] Jian-wei GU, Emily YOUNG, Zhi-jun PAN, Kevan B. TUCKER, Megan SHPARAGO, Min HUANG, Amelia Purser BAILEY. SD大鼠长期高盐饮食可导致其高血压并改变肾细胞因子基因表达谱[J]. 北京大学学报（医学版）, 2009, 41(5): 505 -515 .
[9] 李伟军, 邢晓芳, 曲立科, 孟麟, 寿成超. PRL-3基因C104S位点突变体和CAAX缺失体的构建及表达[J]. 北京大学学报（医学版）, 2009, 41(5): 516 -520 .
[10] 丰雷, 王玉凤, 曹庆久. 哌甲酯对注意缺陷多动障碍儿童平衡功能影响的开放性研究[J]. 北京大学学报（医学版）, 2007, 39(3): 304 -309 .
ISSN 1671-167X
CN 11-4691/R
主管单位：中华人民共和国教育部
主办单位：北京大学
地址： 北京市海淀区学院路38号 北京大学医学部 《北京大学学报（医学版）》
邮编：100191
电话：010-82801551
Email： xbbjb2@bjmu.edu.cn

《北京大学学报（医学版）》
微信公众号
版权所有 © 2018 《北京大学学报（医学版）》编辑部